Trial reportEating and weight disorders : EWD2021
An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.
Trial report in Eating and weight disorders : EWD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Bariatric-Metabolic Surgery is the Most Effective Intervention in Reducing Food Addiction Symptoms: A Systematic Review and Meta-Analysis.Obesity surgery · 2024Pooled it
- Is binge eating associated with poor weight loss outcomes in people with a high body weight? A systematic review with meta-analyses.Eating and weight disorders : EWD · 2023Pooled it
- Feasibility and Preliminary Efficacy of an Online Cardiovascular Disease Prevention Randomised Controlled Trial Targeting Addictive and Compulsive Overeating Among Australian Young Adults.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025Trial
- Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy.Obesity science & practice · 2026Review
- Review
- GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis.Journal of the Endocrine Society · 2025Review
- Pharmacological management of binge eating disorder.The mental health clinician · 2025Article
- The Interplay Between Psychological and Neurobiological Predictors of Weight Regain: A Narrative Review.Nutrients · 2025Review
- Increased odds of metabolic syndrome among adults with depressive symptoms or antidepressant use.Translational psychiatry · 2025Article
- Food addiction and associated factors in newly diagnosed patients with schizophrenia: a cross-sectional comparison with siblings and healthy controls.Journal of eating disorders · 2025Article
- The impact of weight loss interventions on disordered eating symptoms in people with overweight and obesity: a systematic review & meta-analysis.EClinicalMedicine · 2025Article
- TOWARD: a metabolic health intervention that improves food addiction and binge eating symptoms.Frontiers in psychiatry · 2025Article
- The Greater the Number of Altered Eating Behaviors in Obesity, the More Severe the Psychopathology.Nutrients · 2024Article
- Food Addiction.Brain sciences · 2024Review
- Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges.Alpha psychiatry · 2024Review
- Food Cravings and Obesity in Women with Polycystic Ovary Syndrome: Pathophysiological and Therapeutic Considerations.Nutrients · 2024Review
- Influence ofBiomedicines · 2024Article
- Social, clinical, and policy implications of ultra-processed food addiction.BMJ (Clinical research ed.) · 2023Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBinge eating disorder (BED) has a considerable clinical relevance by virtue of its high numerous psychiatric and medical comorbidities; among the latter, the most frequent is obesity. Available treatments for BED have shown frequent relapse of binges or weight regain in the long term. The new combination of naltrexone and bupropion sustained release (NB) has proved to be effective for weight loss among obese patients. As NB acts on hypothalamic and reward circuits, that seem involved in the pathogenesis and maintenance of BED symptoms, this study aims to evaluate the efficacy of NB in improving pathological eating behavior and losing weight in BED patients.
methodsIn this preliminary study, 23 obese-BED patients and a control group of 20 obese non-BED patients (respectively, Groups 1 and 2) who had previously undergone at least 5 unsuccessful weight-loss programs were treated with NB in addition to modified life style. Evaluation at t0 and after 16 weeks of treatment (t1) included anthropometric measurement, eating behavior assessment and psychopathological questionnaires (EDE-Q, BES, YFAS, BDI and STAI).
resultsA significant and similar weight loss (ΔBMI% ≈ 8%) was evident for both groups. Pathological eating behavior (i.e., binge, grazing, emotional eating, craving for carbohydrates, and post-dinner eating), BES score and YFAS severity significantly improved, especially among BED. NB was well tolerated and drop-out rate was low.
conclusionTreatment with NB, in addition to a reduced-calorie diet and increased physical activity, seems an effective and well-tolerated option for improving pathological eating behavior and losing weight in obese-BED patients. LEVEL OF EVIDENCE: Level III case-control study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.